Prevymis (Letermovir)

 Prevymis is a CMV DNA terminase complex inhibitor used for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).

Recommended Dosage: Prevymis Tablet is administered with or without food. Swallow tablets whole. Prevymis Injection is administered by intravenous infusion via a peripheral catheter or central venous line at a constant rate over 1 hour. Do not administer it as an intravenous bolus injection.

The recommended dosage is 480 mg administered orally or intravenously once daily. Initiate therapy between Day 0 and 28’th post-transplantation (prior to or after engraftment), and continue through Day 100’th post-transplantation.

Use prevymis injection, which contains hydroxypropyl betadex, only in those who are unable to take oral therapy. Patients should be switched to oral Prevymis as promptly as they are able to take oral medications. Prevymis injection and tablet may be used interchangeably at the discretion of the health specialist, and no dosage adjustment is required when switching formulations.

If Prevymis is co-administered with drug cyclosporine, the dosage of Prevymis should be reduced to 240 mg once daily.

• If medicine cyclosporine is initiated after initiating Prevymis, the next dose of Prevymis should be reduced to 240 mg once daily.
• If medicine cyclosporine is discontinued after initiating Prevymis, the next dose of Prevymis should be reduced to 480 mg once daily.
• If dosing of medicine cyclosporine is temporarily interrupted because of high cyclosporine levels, no dose adjustment is required. 

• Those with creatinine clearance (CLcr) higher than 10 mL/min, no dose adjustment of prevymis 240 mg is needed on behalf of renal impairment. In those with CLcr less than 50 mL/min receiving this injection, accumulation of the intravenous vehicle, hydroxypropyl betadex, may occur. Precisely monitor serum creatinine levels in these patients.
• No dosage adjustment of Prevymis is needed for those with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Drug Prevymis is not recommended for those with severe (Child-Pugh Class C) hepatic impairment. 
• Concomitant use of prevymis 480 mg tablet and certain drugs may be responsible for potentially significant drug interactions, some of which may lead to side effects or reduced therapeutic effect of Prevymis or the concomitant medicinal products. 
• Use Letermovir with caution along with medicinal products that are CYP3A substrates with narrow therapeutic ranges (fentanyl, alfentanil, and quinidine) as co-administration may be responsible for increasing in the plasma concentrations of CYP3A substrates. Precise monitoring or dose adjustment of co-administered CYP3A substrates is required. 
• Letermovir is an inducer (moderate) of transporters and enzymes. Induction may give rise to reduced plasma concentrations of some metabolized and transported medicines. TDM or therapeutic drug monitoring is therefore needed for voriconazole. Avoid the concomitant use of dabigatran due to risk of reduced dabigatran efficacy.
• Increased monitoring of tacrolimus, cyclosporine, sirolimus is generally required the initial a couple of weeks after starting and ending medication letermovir 240 mg as well as after changing it’s route of administration.
• Prevymis contains lactose monohydrate. Those with rare hereditary complications of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should avoid taking this medicine. This medication contains less than 1 mmol sodium (23 mg) per tablet, that is to designate essentially ‘sodium-free’.
• Letermovir is not recommended while breastfeeding, during pregnancy and in women of childbearing age not using contraception. It is not known whether this medicine is excreted in milk. Do not exclude a risk to the newborns and infants.

What documents are required to import PREVYMIS to India?

PREVYMIS (Letermovir) injection/tablet can be imported by patients or government hospitals on the name of the patients only. 

The following documentation required to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity Proof (issued by government of India)

How does order be confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor
• Import permit if applicable

Is PREVYMIS available in India?

PREVYMIS (Letermovir injection/tablet) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input

• On availability of Prevymis in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
• Medicine Price.
• Finding Genuine and reliable source from Canada, Europe, USA and Australia
• Ensuring 100% transparency.

PREVYMIS can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of PREVYMIS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for PREVYMIS- letermovir price in India. 

We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the PREVYMIS (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Prevymis®?

Letermovir is Generic Name for the trade name drug Prevymis®.

What is the Manufacturer Name of Prevymis®?

Prevymis® is manufactured by Merck. 

Is Prevymis® approved by the FDA?

Yes, Prevymis® is approved by the FDA. Date of first/initial approval: November 8, 2017.

Where can I get Prevymis® at the best price in India?

To get the best Prevymis- Letermovir price in India, contact Indian Pharma Network (a WHO-GDP and ISO 9001:2008 authorized Company). A valid medical prescription is required while buying Prevymis®.

What is the dosage and form of Prevymis® supplied?

Prevymis® is supplied as Tablet: 240 mg; 480 mg; and Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) in a single-dose vial.

What are the most common side effects with Prevymis®? 

The most common side effects with Prevymis® include: cough, nausea, diarrhea, peripheral edema, headache, vomiting, fatigue, and abdominal pain. 

How much does Prevymis® cost in India?

The prevymis cost in India is less and can vary. In order to procure this medicinal product authentically, you Can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Prevymis®?

Store Prevymis tablets/injections at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store tablets in the original package until use and injections in the original carton to protect from exposure to light.

Is it safe to buy Prevymis® online from India? 

Yes, You can buy Prevymis online in India at the best price from the Indian Pharma Network (IPN) if Prevymis® has not been approved or is not available in your country.

What are the Highlights of prescribing information for Prevymis®?

Click Here to download full  Prevymis prescribing information.